2026-05-02

OSINT: Energy commodity prices surge over 70% since Jan 1, 2026

OSINT: Europe Poised for Economic Revival by 2030 with Major Policy Overhaul

CFTC 4 speculator at extreme long - contrarian bear signal

CFTC 1 speculator at extreme short - contrarian bull signal

OSINT: U.S. Navy Seizes Iranian Cargo Ships and Tankers, Trump Announces

OSINT: Trump to Review Iran's Proposal, Doubts Acceptability

OSINT: Carney warns Canada‑US ties now a weakness, could hit markets

OSINT: Trump hints at possible resumption of strikes on Iran

Oil -2.98% - significant selloff

ETH ETF outflow of $177M - institutional selling

BTC ETF outflow of $165M - institutional selling

USDC/USDT has $65.2M volume but only $884K liquidity - thin market, slippage risk

USDC/USDT has $101.6M volume but only $884K liquidity - thin market, slippage risk

WETH/USDT has $11.5M volume but only $986K liquidity - thin market, slippage risk

DAI/USDT has $9.1M volume but only $824K liquidity - thin market, slippage risk

USDC/USDT has $140.9M volume but only $884K liquidity - thin market, slippage risk

WETH/USDT has $10.5M volume but only $924K liquidity - thin market, slippage risk

USDC/USDT has $147.0M volume but only $884K liquidity - thin market, slippage risk

SOL/USDC has $8.1M volume but only $616K liquidity - thin market, slippage risk

WETH/USDT has $9.5M volume but only $922K liquidity - thin market, slippage risk

OSINT: Trump downplays worries as law‑enforcement presence noted

OSINT: SEC Chair Says Current Laws Can't Keep Pace with Crypto Growth

FDA approves NORPACE CR (Pfizer) - new revenue stream

FDA approves MEDROL (Pfizer) - new revenue stream

FDA approves LINEZOLID (Pfizer) - new revenue stream

FDA approves HEMABATE (Pfizer) - new revenue stream

FDA approves drug (Pfizer) - new revenue stream

FDA approves COLESTID (Pfizer) - new revenue stream

FDA approves CYKLOKAPRON (Pfizer) - new revenue stream

FDA approves ZYVOX (Pfizer) - new revenue stream

FDA approves VELSIPITY (Pfizer) - new revenue stream

FDA approves SYNAREL (Pfizer) - new revenue stream

FDA approves CANCIDAS (Merck) - new revenue stream

FDA approves drug (Merck) - new revenue stream

FDA approves EVISTA (Lilly) - new revenue stream

FDA approves ALIMTA (Lilly) - new revenue stream

FDA approves INSULIN LISPRO (Lilly) - new revenue stream

FDA approves HUMATROPE (Lilly) - new revenue stream

FDA approves drug (Lilly) - new revenue stream

FDA approves EMTRIVA (Gilead) - new revenue stream

FDA approves TRUVADA (Gilead) - new revenue stream

FDA approves LETAIRIS (Gilead) - new revenue stream

FDA approves drug (Gilead) - new revenue stream

FDA approves CAYSTON (Gilead) - new revenue stream

FDA approves SOTYKTU (Bristol) - new revenue stream

FDA approves CAMZYOS (Bristol) - new revenue stream

FDA approves drug (Bristol) - new revenue stream

FDA approves EVOTAZ (Bristol) - new revenue stream

FDA approves ONUREG (Bristol) - new revenue stream

FDA approves POMALYST (Bristol) - new revenue stream

FDA approves AVONEX (Biogen) - new revenue stream

FDA approves drug (Biogen) - new revenue stream

FDA approves BLINCYTO (Amgen) - new revenue stream

FDA approves ARANESP (Amgen) - new revenue stream

FDA approves VECTIBIX (Amgen) - new revenue stream

FDA approves SENSIPAR (Amgen) - new revenue stream

FDA approves PROLIA (Amgen) - new revenue stream

FDA approves PROCRIT (Amgen) - new revenue stream

FDA approves NPLATE (Amgen) - new revenue stream

FDA approves NEUPOGEN (Amgen) - new revenue stream

FDA approves NEULASTA (Amgen) - new revenue stream

FDA approves drug (AbbVie) - new revenue stream

FDA approves DEPAKOTE (AbbVie) - new revenue stream

FDA approves FENOFIBRIC ACID (AbbVie) - new revenue stream

FDA approves FML (AbbVie) - new revenue stream

FDA approves MEMANTINE HYDROCHLORIDE (AbbVie) - new revenue stream

FDA approves VYALEV (AbbVie) - new revenue stream

FDA approves drug (Abbott) - new revenue stream

CRH plc search volume spiked +100 pts - unusual interest

Allegion search volume spiked +94 pts - unusual interest

Bristol Myers Squibb search volume spiked +56 pts - unusual interest

OSINT: SEC Chair Says Current Laws Can't Keep Pace with Crypto Growth

Q2-2025: Beat consensus by 8.4% - EPS $2.16 vs $1.9927 estimate

Q3-2025: Missed consensus by 5.4% - EPS $2.1 vs $2.2193 estimate

Q2-2025: Beat consensus by 32.9% - EPS $0.78 vs $0.5869 estimate

Q4-2025: Beat consensus by 14.3% - EPS $0.66 vs $0.5775 estimate

Q1-2025: Beat consensus by 37.5% - EPS $0.92 vs $0.6693 estimate

Q3-2025: Beat consensus by 36.0% - EPS $0.87 vs $0.6397 estimate

Q2-2025: Beat consensus by 9.2% - EPS $0.77 vs $0.7054 estimate

Q3-2025: Beat consensus by 10.1% - EPS $1.13 vs $1.0265 estimate

Q4-2025: Beat consensus by 8.9% - EPS $1.41 vs $1.2945 estimate

Q3-2025: Beat consensus by 19.8% - EPS $1.43 vs $1.1934 estimate

Beat consensus by 26.8% - EPS $0.8 vs $0.631 estimate

Q3-2025: Missed consensus by 20.2% - EPS $0.58 vs $0.7268 estimate

Q1-2026: Missed consensus by 18.5% - EPS $0.33 vs $0.4048 estimate

Q4-2025: Missed consensus by 34.8% - EPS $0.34 vs $0.5211 estimate

Q4-2026: Beat consensus by 9.5% - EPS $1.9 vs $1.7355 estimate

Q3-2026: Beat consensus by 15.0% - EPS $3.06 vs $2.6612 estimate

Q3-2026: Beat consensus by 16.1% - EPS $4.1 vs $3.5329 estimate

Q2-2026: Beat consensus by 9.4% - EPS $3.11 vs $2.8425 estimate

Q1-2026: Beat consensus by 8.9% - EPS $2.61 vs $2.3972 estimate

Q1-2026: Beat consensus by 7.8% - EPS $2.84 vs $2.6356 estimate

Missed consensus by 6.2% - EPS $2.01 vs $2.142 estimate

Q4-2025: Beat consensus by 5.5% - EPS $1.82 vs $1.7248 estimate

Q4-2025: Beat consensus by 8.2% - EPS $1.28 vs $1.1828 estimate

Q3-2025: Beat consensus by 20.5% - EPS $1.11 vs $0.9212 estimate

Beat consensus by 38.6% - EPS $0.7 vs $0.505 estimate

Beat consensus by 5.2% - EPS $4.73 vs $4.497 estimate

Missed consensus by 78.7% - EPS $0.43 vs $2.016 estimate

Q3-2025: Beat consensus by 9.6% - EPS $1.86 vs $1.6968 estimate

Q2-2025: Beat consensus by 15.1% - EPS $1.69 vs $1.4685 estimate

Q1-2025: Beat consensus by 7.6% - EPS $1.34 vs $1.2457 estimate

Q3-2000: Beat consensus by 10.5% - EPS $1.03 vs $0.9322 estimate

Q4-2025: Missed consensus by 6.9% - EPS $0.55 vs $0.5908 estimate

Q1-2026: Beat consensus by 5.9% - EPS $1.32 vs $1.2464 estimate

Q3-2025: Missed consensus by 10.9% - EPS $3.39 vs $3.8047 estimate

Q2-2025: Beat consensus by 6.3% - EPS $3.67 vs $3.4541 estimate

Beat consensus by 59.0% - EPS $23.41 vs $14.723 estimate

Q2-2026: Beat consensus by 76.3% - EPS $6.2 vs $3.5172 estimate

Q1-2026: Beat consensus by 27.8% - EPS $1.22 vs $0.9543 estimate

Q1-2000: Missed consensus by 5.1% - EPS $0.58 vs $0.6111 estimate

Q2-2026: Beat consensus by 38.7% - EPS $0.69 vs $0.4976 estimate

Q4-2025: Missed consensus by 8.4% - EPS $0.41 vs $0.4476 estimate

Q3-2025: Missed consensus by 39.3% - EPS $0.31 vs $0.5106 estimate

Q1-2026: Missed consensus by 14.9% - EPS $0.35 vs $0.4112 estimate

Q3-2000: Missed consensus by 10.9% - EPS $0.22 vs $0.2469 estimate

Q4-2025: Missed consensus by 9.5% - EPS $0.52 vs $0.5743 estimate

Q3-2025: Missed consensus by 7.8% - EPS $0.61 vs $0.6616 estimate

Q1-2026: Missed consensus by 6.3% - EPS $0.56 vs $0.5978 estimate

Q2-2026: Beat consensus by 14.2% - EPS $0.5 vs $0.4379 estimate

Q1-2026: Beat consensus by 66.9% - EPS $3.01 vs $1.8031 estimate

Q4-2025: Missed consensus by 10.3% - EPS $3.47 vs $3.8682 estimate

Q1-2025: Beat consensus by 20.7% - EPS $-0.71 vs $-0.8954 estimate

Q4-2025: Missed consensus by 463.3% - EPS $-4.2 vs $-0.7456 estimate

Q3-2025: Beat consensus by 1142.6% - EPS $12.85 vs $-1.2325 estimate

Q4-2025: Beat consensus by 7.4% - EPS $1.7 vs $1.5822 estimate

Q1-2026: Beat consensus by 16.1% - EPS $1.78 vs $1.5331 estimate

Q2-2025: Beat consensus by 7.0% - EPS $1.56 vs $1.4585 estimate

Beat consensus by 19.5% - EPS $1.7 vs $1.423 estimate

Q3-2025: Beat consensus by 5.6% - EPS $1.9 vs $1.7993 estimate

Q3-2000: Missed consensus by 17.9% - EPS $0.22667 vs $0.2761 estimate

Beat consensus by 7.4% - EPS $1.76 vs $1.639 estimate

Q3-2026: Beat consensus by 10.1% - EPS $1.58 vs $1.4355 estimate

Q4-2025: Missed consensus by 7.3% - EPS $0.25 vs $0.2698 estimate

Q4-2000: Beat consensus by 5.4% - EPS $0.84 vs $0.7971 estimate

Q4-2025: Beat consensus by 12.7% - EPS $3.34 vs $2.9641 estimate

Beat consensus by 10.5% - EPS $2.75 vs $2.488 estimate

Q2-2026: Beat consensus by 7.0% - EPS $3.79 vs $3.5431 estimate

Beat consensus by 9.9% - EPS $2.27 vs $2.065 estimate

Beat consensus by 9.1% - EPS $3.11 vs $2.851 estimate

Q3-2025: Missed consensus by 8.4% - EPS $2.18 vs $2.3803 estimate

Q4-2025: Missed consensus by 8.2% - EPS $0.58 vs $0.6316 estimate

Q4-2025: Beat consensus by 5.7% - EPS $11.44 vs $10.8277 estimate

Q2-2025: Beat consensus by 49.8% - EPS $12.89 vs $8.6063 estimate

Beat consensus by 21.0% - EPS $11.83 vs $9.78 estimate

Beat consensus by 90.5% - EPS $1.2 vs $0.63 estimate

Q4-2025: Beat consensus by 15.3% - EPS $0.68 vs $0.5896 estimate

Q2-2025: Beat consensus by 6.1% - EPS $4.38 vs $4.1275 estimate

Q1-2026: Beat consensus by 11.3% - EPS $3.6 vs $3.2354 estimate

Q3-2025: Beat consensus by 9.2% - EPS $0.73351 vs $0.6715 estimate

Beat consensus by 27.7% - EPS $0.82 vs $0.642 estimate

Q2-2025: Beat consensus by 5.8% - EPS $1.4 vs $1.3228 estimate

Q4-2025: Missed consensus by 6.1% - EPS $1.23 vs $1.3103 estimate

Q3-2025: Beat consensus by 9.4% - EPS $1.34 vs $1.2251 estimate

Q1-2025: Beat consensus by 12.3% - EPS $1.33 vs $1.1847 estimate

Q1-2026: Beat consensus by 28.4% - EPS $2.68 vs $2.0868 estimate

Q1-2026: Beat consensus by 21.6% - EPS $1.92 vs $1.5794 estimate

Q2-2025: Beat consensus by 26.9% - EPS $1.79 vs $1.4101 estimate

Q3-2025: Beat consensus by 34.3% - EPS $1.64 vs $1.2213 estimate

Q4-2025: Beat consensus by 51.3% - EPS $3.47 vs $2.2935 estimate

Q3-2025: Beat consensus by 15.2% - EPS $2.52 vs $2.1881 estimate

Beat consensus by 13.0% - EPS $2.47 vs $2.186 estimate

Q1-2026: Beat consensus by 278.6% - EPS $0.49 vs $-0.2744 estimate

Q2-2025: Beat consensus by 38.1% - EPS $2.38 vs $1.7233 estimate

Q3-2025: Missed consensus by 131.1% - EPS $-0.12 vs $0.3853 estimate

Beat consensus by 25.7% - EPS $0.46 vs $0.366 estimate

Q1-2025: Beat consensus by 13.1% - EPS $0.29 vs $0.2563 estimate

Q2-2025: Missed consensus by 31.9% - EPS $1.76 vs $2.5831 estimate

Beat consensus by 75.0% - EPS $4.22 vs $2.411 estimate

Q2-2025: Beat consensus by 10.4% - EPS $3.58 vs $3.2413 estimate

Q3-2025: Beat consensus by 14.1% - EPS $4.26 vs $3.7323 estimate

Q1-2025: Beat consensus by 9.5% - EPS $0.6 vs $0.5479 estimate

Missed consensus by 17.1% - EPS $0.32 vs $0.386 estimate

Q4-2025: Missed consensus by 5.5% - EPS $1.51 vs $1.5978 estimate

Q4-2025: Missed consensus by 15.7% - EPS $0.84 vs $0.9965 estimate

Q2-2025: Beat consensus by 23.7% - EPS $1.17 vs $0.9458 estimate

Q1-2025: Beat consensus by 24.5% - EPS $1.01 vs $0.8112 estimate

Q3-2025: Beat consensus by 6.5% - EPS $1.24 vs $1.1643 estimate

Q3-2025: Beat consensus by 7.7% - EPS $3.39 vs $3.1472 estimate

Q2-2025: Beat consensus by 7.2% - EPS $3.85 vs $3.5928 estimate

Q3-2025: Beat consensus by 6.4% - EPS $4.35 vs $4.0901 estimate

Q4-2025: Beat consensus by 14.6% - EPS $4.88 vs $4.2594 estimate

Q3-2025: Beat consensus by 22.2% - EPS $0.21 vs $0.1718 estimate

Q2-2025: Beat consensus by 13.9% - EPS $0.16 vs $0.1405 estimate

Q4-2025: Beat consensus by 6.5% - EPS $0.25 vs $0.2348 estimate

Q4-2025: Beat consensus by 117.6% - EPS $1.49 vs $0.6848 estimate

Q3-2025: Beat consensus by 22.6% - EPS $0.82 vs $0.6686 estimate

Q1-2026: Beat consensus by 28.3% - EPS $1.05 vs $0.8181 estimate

Q1-2026: Beat consensus by 11.4% - EPS $2.4 vs $2.1545 estimate

Q4-2025: Missed consensus by 10.0% - EPS $2.56 vs $2.8434 estimate

OSINT: Carney warns Canada‑US ties now a weakness, could hit markets

OSINT: Trump to Review Iran's Proposal, Doubts Acceptability

OSINT: Trump hints at possible resumption of strikes on Iran

OSINT: SEC Chair Says Current Laws Can't Keep Pace with Crypto Growth

OSINT: Trump downplays worries as law‑enforcement presence noted

OSINT: Trump to Review Iran's Proposal, Doubts Acceptability

OSINT: Carney warns Canada‑US ties now a weakness, could hit markets

OSINT: Trump hints at possible resumption of strikes on Iran

OSINT: Trump downplays worries as law‑enforcement presence noted

Financial conditions loosening - NFCI at -0.52, liquidity supportive